{"organizations": [], "uuid": "c93c4a176c7ae6b45c81dfe5e8ba556cfbd4af98", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/30/globe-newswire-arbutus-announces-conference-call-to-provide-a-corporate-update-and-first-quarter-2018-financial-results.html", "country": "US", "domain_rank": 767, "title": "Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.276, "site_type": "news", "published": "2018-04-30T17:00:00.000+03:00", "replies_count": 0, "uuid": "c93c4a176c7ae6b45c81dfe5e8ba556cfbd4af98"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/30/globe-newswire-arbutus-announces-conference-call-to-provide-a-corporate-update-and-first-quarter-2018-financial-results.html", "ord_in_thread": 0, "title": "Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results", "locations": [], "entities": {"persons": [{"name": "arbutus biopharm", "sentiment": "negative"}], "locations": [{"name": "warminster", "sentiment": "none"}, {"name": "columbia", "sentiment": "none"}, {"name": "vancouver", "sentiment": "none"}, {"name": "pa.", "sentiment": "none"}], "organizations": [{"name": "arbutus arbutus biopharma corporation", "sentiment": "none"}, {"name": "hbv", "sentiment": "none"}, {"name": "eastern time", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2018 financial results and provide a corporate update.\nTo access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com . Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.\nAn archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 4169558.\nAbout Arbutus\nArbutus Biopharma Corporation is a publicly traded (Nasdaq:ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care (SOC) and contribute to a curative combination regimen to improve patient outcomes and deliver a potential cure for HBV. For more information, visit www.arbutusbio.com .\nContact Information\nInvestors\nTiffany Tolmie\nManager, Investor Relations\nPhone: 604-419-3200\nEmail: ttolmie@arbutusbio.com\nMedia\nDavid Schull\nRusso Partners\nPhone: 858-717-2310\nEmail: david.schull@russopartnersllc.com\nSource:Arbutus Biopharma Corporation", "external_links": ["https://www.globenewswire.com/Tracker?data=ZU3io7SuoPwjHUZ53PUzKh-vuDdwSS3sKnOX4CZNZRjSm84h2QUsApzWJLsfVDI8xbwCVtebtx0cK0MotXZgbo4XnXAla1xePg3peKqw4U17T-ox2_pLLUz1uN-gq2R1", "https://www.globenewswire.com/Tracker?data=nweD06ye0FbLrPDNWdLlPLx2X2Kej_JjQsV875jcMteTEIu7oRL4N3wfNmZKgofBk2a2E7vmyLEeXJeja__DSc0ukoiF1JcP1TtzSSZuLTc=", "https://www.globenewswire.com/Tracker?data=nweD06ye0FbLrPDNWdLlPM9zrLpdV-kENngGynOBnMoI9eN7qE4dUFbuD9QwQoSVqKG7EQb27kw5nE8sPqThZl8S6qS_P8zPw5_1LwLy02U=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/be474abd-3f6d-4270-a58e-1e6ee5c80bb2", "https://www.globenewswire.com/Tracker?data=oKOB6bA1wTjEyU8-23PV0I0NhvjV_2PJSVhd9DfNNz6O4tbaLI9u-CAWj5SNXvwwfzxOpuNxWElJQgclu6SsAks1OVFZsWJ_XBRxi7mdLVc="], "published": "2018-04-30T17:00:00.000+03:00", "crawled": "2018-04-30T17:29:10.005+03:00", "highlightTitle": ""}